Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol.

  • Van Ganse, Eric
  • Texier, Nathalie
  • Dima, Alexandra L.
  • Laforest, Laurent
  • Ferrer, Montserrat
  • Hernández, Gimena
  • Schuck, Stéphane
  • Herbage, Sandrine
  • Vial, Delphine
  • Bruin, Marijn de
  • ASTRO-LAB group
ASTRO-LAB is funded by the European Commission through the Seventh Framework Program (FP7-Grant Agreement n° 282 593) and gathers seven partners in a Consortium: Université Claude Bernard Lyon 1, University of Nottingham, Kappa Santé SAS, Cegedim Strategic Data Medical Research Limited, University of Amsterdam, Consortio Mar Parc de Salut de Barcelona and Lyon Ingénierie Projets.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The Inhaler Technique Questionnaire (InTeQ): development and validation of a brief patient-reported measure

  • Lizano-Barrantes, Catalina
  • Garin Boronat, Olatz, 1979-
  • Dima, Alexandra L.
  • Van Ganse, Eric
  • Bruin, Marijn de
  • Belhassen, Manon
  • Mayoral, Karina
  • Pont Acuña, Àngels
  • Ferrer Forés, Maria Montserrat
There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23-1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups' global score differences were statistically significant between patients reporting having "Discussed in detail" or having "Not discussed/Only in general" the inhaler technique with their healthcare providers (p = 0.023). The Cronbach's alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device., The research leading to these results has received funding from the European Community 7th Framework (FP7/2007–2013) under grant agreement number 282593, and the H2020 programme (MSCA-IF) under grant agreement number 706028 for A.L.D. during manuscript preparation. The following researchers have worked on this manuscript while funded by grants: C.L.-B. (University of Costa Rica OAICE-85-2019), K.M. (Instituto de Salud Carlos III FEDER: Fondo Europeo de Desarrollo Regional FI16/00071) and A.L.D. (IDEXLYON 16-IDEX-0005). The Health Services Research Group, IMIM, received funding from Generalitat de Catalunya (2017 SGR 452). Funding information for this article has been deposited with the Crossref Funder Registry. The funding agreements ensure the authors’ independence in designing the study, interpreting the data, and writing and publishing the report.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study

  • Hernández, Gimena
  • Garin Boronat, Olatz, 1979-
  • Dima, Alexandra L.
  • Pont Acuña, Àngels
  • Martí-Pastor, Marc
  • Alonso Caballero, Jordi
  • Van Ganse, Eric
  • Laforest, Laurent
  • Bruin, Marijn de
  • Mayoral, Karina
  • Serra-Sutton, Vicky
  • Ferrer Forés, Maria Montserrat
  • ASTRO-LAB group
BACKGROUND: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. OBJECTIVE: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. METHODS: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes. RESULTS: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and P=.01) were of moderate magnitude with effect sizes around 0.5. CONCLUSIONS: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of this administration form., Financial support for this study was provided by the European Union Seventh Framework Programme FP7 (ASTROLAB project EC HEALTH-F5-2011-282593), Instituto de Salud Carlos III FEDER (PI12/00772), Fondo de Investigación Sanitaria, ISCIII (PI15/00449), Fondo de Investigación Sanitaria, ISCIII (PI16/00130), Fondo de Investigación Sanitaria, ISCIII (FI16/00071), ISCIII (Río Hortega, CM15/00167), and DIUE of Generalitat de Catalunya (2017 SGR 452, 2014 SGR 748). The funding agreement ensures the authors’ independence in designing the study, interpreting the data, and writing and publishing the report. The authors would like to acknowledge Aurea Martin for her help in the English editing and proofreading process, and in finalizing this manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies

  • Hernández, Gimena
  • Ávila Pacheco, Mónica Marcela, 1984-
  • Pont Acuña, Àngels
  • Garin Boronat, Olatz, 1979-
  • Alonso Caballero, Jordi
  • Laforest, Laurent
  • Cates, Christopher J.
  • Ferrer Forés, Maria Montserrat
  • ASTRO-LAB group
Background: Although several systematic reviews investigated the safety of long-acting beta–agonists (LABAs) in asthma, they mainly addressed randomized clinical trials while evidence from non-randomized studies has been mostly neglected. We aim to assess the risk of serious adverse events in adults and children with asthma treated with LABAs and Inhaled Corticosteroids (ICs), compared to patients treated only with ICs, from published non-randomized studies. Methods: The protocol registration number was CRD42012003387 (http://www.crd.york.ac.uk/Prospero webcite). Literature search for articles published since 1990 was performed in MEDLINE and EMBASE. Two authors selected studies independently for inclusion and extracted the data. A third reviewer resolved discrepancies. To assess the risk of serious adverse events, meta-analyses were performed calculating odds ratio summary estimators using random effect models when heterogeneity was found, and fixed effect models otherwise. Results: Of 4,415 candidate articles, 1,759 abstracts were reviewed and 220 articles were fully read. Finally, 19 studies met the inclusion criteria. Most of them were retrospective observational cohorts. Sample sizes varied from 50 to 514,216. The meta-analyses performed (69,939-624,303 participants according to the outcome considered) showed that odds ratio of the LABAs and ICs combined treatment when compared with ICs alone was: 0.88 (95% CI 0.69-1.12) for asthma-related hospitalization; 0.75 (95% CI 0.66-0.84) for asthma-related emergency visits; 1.02 (95% CI 0.94-1.10) for systemic corticosteroids; and 0.95 (95% CI 0.9-1.0) for the combined outcome. Conclusions: Evidence from observational studies shows that the combined treatment of LABAs and ICs is not associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were prospective design, paediatric population and inclusion of mortality as a primary outcome., Financial support for this study was provided by the Health Research Fund (European Union FP7, ASTROLAB project EC HEALTH-F5-2011-282593); the Agency for Management of University and Research Grants AGAUR (2012FI_B1 00177); and a Fundación Carolina Fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol.

  • Van Ganse, Eric
  • Texier, Nathalie
  • Dima, Alexandra L.
  • Laforest, Laurent
  • Ferrer, Montserrat
  • Hernández, Gimena
  • Schuck, Stéphane
  • Herbage, Sandrine
  • Vial, Delphine
  • Bruin, Marijn de
  • ASTRO-LAB group
ASTRO-LAB is funded by the European Commission through the Seventh Framework Program (FP7-Grant Agreement n° 282 593) and gathers seven partners in a Consortium: Université Claude Bernard Lyon 1, University of Nottingham, Kappa Santé SAS, Cegedim Strategic Data Medical Research Limited, University of Amsterdam, Consortio Mar Parc de Salut de Barcelona and Lyon Ingénierie Projets.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Inhaler Technique Questionnaire (InTeQ): development and validation of a brief patient-reported measure

  • Lizano-Barrantes, Catalina
  • Garin Boronat, Olatz, 1979-
  • Dima, Alexandra L.
  • Van Ganse, Eric
  • Bruin, Marijn de
  • Belhassen, Manon
  • Mayoral, Karina
  • Pont Acuña, Àngels
  • Ferrer Forés, Maria Montserrat
There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23-1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups' global score differences were statistically significant between patients reporting having "Discussed in detail" or having "Not discussed/Only in general" the inhaler technique with their healthcare providers (p = 0.023). The Cronbach's alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device., The research leading to these results has received funding from the European Community 7th Framework (FP7/2007–2013) under grant agreement number 282593, and the H2020 programme (MSCA-IF) under grant agreement number 706028 for A.L.D. during manuscript preparation. The following researchers have worked on this manuscript while funded by grants: C.L.-B. (University of Costa Rica OAICE-85-2019), K.M. (Instituto de Salud Carlos III FEDER: Fondo Europeo de Desarrollo Regional FI16/00071) and A.L.D. (IDEXLYON 16-IDEX-0005). The Health Services Research Group, IMIM, received funding from Generalitat de Catalunya (2017 SGR 452). Funding information for this article has been deposited with the Crossref Funder Registry. The funding agreements ensure the authors’ independence in designing the study, interpreting the data, and writing and publishing the report.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study

  • Hernández, Gimena
  • Garin Boronat, Olatz, 1979-
  • Dima, Alexandra L.
  • Pont Acuña, Àngels
  • Martí-Pastor, Marc
  • Alonso Caballero, Jordi
  • Van Ganse, Eric
  • Laforest, Laurent
  • Bruin, Marijn de
  • Mayoral, Karina
  • Serra-Sutton, Vicky
  • Ferrer Forés, Maria Montserrat
  • ASTRO-LAB group
BACKGROUND: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. OBJECTIVE: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. METHODS: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes. RESULTS: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and P=.01) were of moderate magnitude with effect sizes around 0.5. CONCLUSIONS: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of this administration form., Financial support for this study was provided by the European Union Seventh Framework Programme FP7 (ASTROLAB project EC HEALTH-F5-2011-282593), Instituto de Salud Carlos III FEDER (PI12/00772), Fondo de Investigación Sanitaria, ISCIII (PI15/00449), Fondo de Investigación Sanitaria, ISCIII (PI16/00130), Fondo de Investigación Sanitaria, ISCIII (FI16/00071), ISCIII (Río Hortega, CM15/00167), and DIUE of Generalitat de Catalunya (2017 SGR 452, 2014 SGR 748). The funding agreement ensures the authors’ independence in designing the study, interpreting the data, and writing and publishing the report. The authors would like to acknowledge Aurea Martin for her help in the English editing and proofreading process, and in finalizing this manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies

  • Hernández, Gimena
  • Ávila Pacheco, Mónica Marcela, 1984-
  • Pont Acuña, Àngels
  • Garin Boronat, Olatz, 1979-
  • Alonso Caballero, Jordi
  • Laforest, Laurent
  • Cates, Christopher J.
  • Ferrer Forés, Maria Montserrat
  • ASTRO-LAB group
Background: Although several systematic reviews investigated the safety of long-acting beta–agonists (LABAs) in asthma, they mainly addressed randomized clinical trials while evidence from non-randomized studies has been mostly neglected. We aim to assess the risk of serious adverse events in adults and children with asthma treated with LABAs and Inhaled Corticosteroids (ICs), compared to patients treated only with ICs, from published non-randomized studies. Methods: The protocol registration number was CRD42012003387 (http://www.crd.york.ac.uk/Prospero webcite). Literature search for articles published since 1990 was performed in MEDLINE and EMBASE. Two authors selected studies independently for inclusion and extracted the data. A third reviewer resolved discrepancies. To assess the risk of serious adverse events, meta-analyses were performed calculating odds ratio summary estimators using random effect models when heterogeneity was found, and fixed effect models otherwise. Results: Of 4,415 candidate articles, 1,759 abstracts were reviewed and 220 articles were fully read. Finally, 19 studies met the inclusion criteria. Most of them were retrospective observational cohorts. Sample sizes varied from 50 to 514,216. The meta-analyses performed (69,939-624,303 participants according to the outcome considered) showed that odds ratio of the LABAs and ICs combined treatment when compared with ICs alone was: 0.88 (95% CI 0.69-1.12) for asthma-related hospitalization; 0.75 (95% CI 0.66-0.84) for asthma-related emergency visits; 1.02 (95% CI 0.94-1.10) for systemic corticosteroids; and 0.95 (95% CI 0.9-1.0) for the combined outcome. Conclusions: Evidence from observational studies shows that the combined treatment of LABAs and ICs is not associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were prospective design, paediatric population and inclusion of mortality as a primary outcome., Financial support for this study was provided by the Health Research Fund (European Union FP7, ASTROLAB project EC HEALTH-F5-2011-282593); the Agency for Management of University and Research Grants AGAUR (2012FI_B1 00177); and a Fundación Carolina Fellowship.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of the safety of long-acting β-agonists in routine asthma care, the ASTRO-LAB protocol

  • Van Ganse, Eric|||0000-0002-7463-9187
  • Texier, Nathalie
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Laforest, Laurent|||0000-0002-3694-7699
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Hernandez, Gimena|||0000-0001-5319-3465
  • Schuck, Stéphane
  • Herbage, Sandrine
  • Vial, Delphine
  • de Bruin, Marijn|||0000-0003-3100-6803
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma, Cross-Sectional Study

  • Hernandez, Gimena|||0000-0001-5319-3465
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Alonso, Jordi|||0000-0001-8627-9636
  • Van Ganse, Eric|||0000-0002-7463-9187
  • Laforest, Laurent|||0000-0002-3694-7699
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Mayoral, K.|||0000-0002-7904-4422
  • Serra Sutton, Vicky|||0000-0002-7852-175X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of asthma on women and men, Comparison with the general population using the EQ-5D-5L questionnaire

  • Hernandez, Gimena|||0000-0001-5319-3465
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Alonso, Jordi|||0000-0001-8627-9636
  • Van Ganse, Eric|||0000-0002-7463-9187
  • Laforest, Laurent|||0000-0002-3694-7699
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Mayoral, K.|||0000-0002-7904-4422
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The aim was to evaluate the impact of asthma on patients' Health-Related Quality of Life (HRQoL) by comparing asthmatic women and men with reference norms, to examine the factors which contributed to an impaired HRQoL, and to identify groups at higher risk. Cross-sectional evaluation of 222 primary care patients with persistent asthma (18-40 years old). HRQoL impact was estimated with the EuroQol-5 Dimensions (EQ-5D), which allows calculating Quality-Adjusted Life-Years (QALYs) by applying society preferences. Participants self-completed the EQ-5D questionnaire online. Telephonic interviews collected information on medication and adherence, and administered the Asthma Control Questionnaire. Severity markers included asthma-related comorbidity, previous oral corticosteroids course prescription, and inhaled corticosteroids daily dose. After bivariate analyses, multiple linear regression models were constructed to examine the relations between HRQoL asthma impact and socio-demographic and clinical variables, using as dependent variable the deviation from general population-based EQ-5D reference norms. Deviation from the EQ-5D index norms was moderate in most age/gender groups (-0.1, which corresponds to 0.6 standard deviations), while it was large in women aged 18-24 years (-0.18, corresponding to 1.1 standard deviations). In regression models, a poor asthma control was the only factor independently associated to HRQoL impact in both women and men: β -0.18 (p<0.001) and -0.15 (p = 0.01) respectively. Translating these β coefficients to QALYs, they are interpretable as 66 fewer days of full health per year in women with uncontrolled asthma and 55 for men, compared with those with controlled asthma. Persistent asthma has a moderately negative HRQoL impact on patients of both genders, and the youngest women have been identified as a high risk group which merits further research. We identified asthma control as the major contributor to impaired HRQoL in patients, regardless of their gender, suggesting that asthma HRQoL impact could be alleviated by achieving a good control of symptoms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Inhaler Technique Questionnaire (InTeQ), Development and Validation of a Brief Patient-Reported Measure

  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Van Ganse, Eric|||0000-0002-7463-9187
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Belhassen, Manon|||0000-0002-9478-5464
  • Mayoral, K.|||0000-0002-7904-4422
  • Pont, Angels|||0000-0002-0602-552X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23-1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups' global score differences were statistically significant between patients reporting having "Discussed in detail" or having "Not discussed/Only in general" the inhaler technique with their healthcare providers (p = 0.023). The Cronbach's alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device.